Female resistance to pneumonia identifies lung macrophage nitric oxide Synthase-3 as a therapeutic target

  1. Zhiping Yang
  2. Yuh-Chin T Huang
  3. Henry Koziel
  4. Rini de Crom
  5. Hartmut Ruetten
  6. Paulus Wohlfart
  7. Reimar W Thomsen
  8. Johnny Kahlert
  9. Henrik Toft Sørensen
  10. Szczepan Jozefowski
  11. Amy Colby
  12. Lester Kobzik  Is a corresponding author
  1. Harvard School of Public Health, United States
  2. US Environmental Protection Agency, United States
  3. Beth Israel Deaconness Medical Center, United States
  4. Erasmus University Medical Center, Netherlands
  5. Sanofi Research and Development, Germany
  6. Aarhus University Hospital, Denmark
  7. Jagiellonian University Medical College, Poland

Abstract

To identify new approaches to enhance innate immunity to bacterial pneumonia, we investigated the natural experiment of gender differences in resistance to infections. Female and estrogen-treated male mice show greater resistance to pneumococcal pneumonia, seen as greater bacterial clearance, diminished lung inflammation and better survival. In vitro, lung macrophages from female mice and humans show better killing of ingested bacteria. Inhibitors and genetically altered mice identify a critical role for estrogen-mediated activation of lung macrophage nitric oxide synthase-3 (NOS3). Epidemiologic data show decreased hospitalization for pneumonia in women receiving estrogen or statins (known to activate NOS3). Pharmacologic targeting of NOS3 with statins or another small-molecule compound (AVE3085) enhanced macrophage bacterial killing, improved bacterial clearance and increased host survival in both primary and secondary (post-influenza) pneumonia. The data identify a novel mechanism for host defense via NOS3 and suggest a potential therapeutic strategy to reduce secondary bacterial pneumonia after influenza.

Article and author information

Author details

  1. Zhiping Yang

    Harvard School of Public Health, Boston, United States
    Competing interests
    No competing interests declared.
  2. Yuh-Chin T Huang

    US Environmental Protection Agency, Chapel Hill, United States
    Competing interests
    No competing interests declared.
  3. Henry Koziel

    Beth Israel Deaconness Medical Center, Boston, United States
    Competing interests
    No competing interests declared.
  4. Rini de Crom

    Erasmus University Medical Center, Rotterdam, Netherlands
    Competing interests
    No competing interests declared.
  5. Hartmut Ruetten

    Sanofi Research and Development, Frankfurt, Germany
    Competing interests
    Hartmut Ruetten, Named as inventor on patents (US 7,179,839; 8,309,608, held by Sanofi, Inc.) describing AVE3085 as a useful compound for cardiovascular indications.
  6. Paulus Wohlfart

    Sanofi Research and Development, Frankfurt, Germany
    Competing interests
    Paulus Wohlfart, Named as inventor on patents (US 7,179,839; 8,309,608, held by Sanofi, Inc.) describing AVE3085 as a useful compound for cardiovascular indications.
  7. Reimar W Thomsen

    Aarhus University Hospital, Aarhus, Denmark
    Competing interests
    No competing interests declared.
  8. Johnny Kahlert

    Aarhus University Hospital, Aarhus, Denmark
    Competing interests
    No competing interests declared.
  9. Henrik Toft Sørensen

    Aarhus University Hospital, Aarhus, Denmark
    Competing interests
    No competing interests declared.
  10. Szczepan Jozefowski

    Jagiellonian University Medical College, Kraków, Poland
    Competing interests
    No competing interests declared.
  11. Amy Colby

    Harvard School of Public Health, Boston, United States
    Competing interests
    No competing interests declared.
  12. Lester Kobzik

    Harvard School of Public Health, Boston, United States
    For correspondence
    lkobzik@hsph.harvard.edu
    Competing interests
    No competing interests declared.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (Harvard Medical Area IACUC) protocol (#03287).

Human subjects: We studied incidence of hospitalized pneumonia associated with use of estrogen and statins in a population-based case-control study based on medical databases in Denmark. Cases of pneumonia were identified as all women who received a first-time principal hospital diagnosis of pneumonia in the former North Jutland and Aarhus Counties, Northern Denmark (1.2 million inhabitants) between 1997 and 2012. Using the Danish Civil Registration System, each case subject was matched with five population control subjects with same age, female gender, and residence in Northern Denmark on the pneumonia index date. The study was approved by the Danish Data Protection Agency (record number: 2013-41-1924). Danish registry data are generally available for research purposes, and, according to Danish law, use of the data does not require informed consent.

Copyright

© 2014, Yang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,910
    views
  • 220
    downloads
  • 45
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Zhiping Yang
  2. Yuh-Chin T Huang
  3. Henry Koziel
  4. Rini de Crom
  5. Hartmut Ruetten
  6. Paulus Wohlfart
  7. Reimar W Thomsen
  8. Johnny Kahlert
  9. Henrik Toft Sørensen
  10. Szczepan Jozefowski
  11. Amy Colby
  12. Lester Kobzik
(2014)
Female resistance to pneumonia identifies lung macrophage nitric oxide Synthase-3 as a therapeutic target
eLife 3:e03711.
https://doi.org/10.7554/eLife.03711

Share this article

https://doi.org/10.7554/eLife.03711

Further reading

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease
    Axelle Amen, Randy Yoo ... Matthijs M Jore
    Research Article

    Circulating sexual stages of Plasmodium falciparum (Pf) can be transmitted from humans to mosquitoes, thereby furthering the spread of malaria in the population. It is well established that antibodies can efficiently block parasite transmission. In search for naturally acquired antibodies targets on sexual stages, we established an efficient method for target-agnostic single B cell activation followed by high-throughput selection of human monoclonal antibodies (mAbs) reactive to sexual stages of Pf in the form of gametes and gametocyte extracts. We isolated mAbs reactive against a range of Pf proteins including well-established targets Pfs48/45 and Pfs230. One mAb, B1E11K, was cross-reactive to various proteins containing glutamate-rich repetitive elements expressed at different stages of the parasite life cycle. A crystal structure of two B1E11K Fab domains in complex with its main antigen, RESA, expressed on asexual blood stages, showed binding of B1E11K to a repeating epitope motif in a head-to-head conformation engaging in affinity-matured homotypic interactions. Thus, this mode of recognition of Pf proteins, previously described only for Pf circumsporozoite protein (PfCSP), extends to other repeats expressed across various stages. The findings augment our understanding of immune-pathogen interactions to repeating elements of the Plasmodium parasite proteome and underscore the potential of the novel mAb identification method used to provide new insights into the natural humoral immune response against Pf.

    1. Immunology and Inflammation
    Yalan Jiang, Pingping He ... Xiaoou Shan
    Research Article

    Type 1 diabetes mellitus (T1DM), known as insulin-dependent diabetes mellitus, is characterized by persistent hyperglycemia resulting from damage to the pancreatic β cells and an absolute deficiency of insulin, leading to multi-organ involvement and a poor prognosis. The progression of T1DM is significantly influenced by oxidative stress and apoptosis. The natural compound eugenol (EUG) possesses anti-inflammatory, anti-oxidant, and anti-apoptotic properties. However, the potential effects of EUG on T1DM had not been investigated. In this study, we established the streptozotocin (STZ)-induced T1DM mouse model in vivo and STZ-induced pancreatic β cell MIN6 cell model in vitro to investigate the protective effects of EUG on T1DM, and tried to elucidate its potential mechanism. Our findings demonstrated that the intervention of EUG could effectively induce the activation of nuclear factor E2-related factor 2 (NRF2), leading to an up-regulation in the expressions of downstream proteins NQO1 and HMOX1, which are regulated by NRF2. Moreover, this intervention exhibited a significant amelioration in pancreatic β cell damage associated with T1DM, accompanied by an elevation in insulin secretion and a reduction in the expression levels of apoptosis and oxidative stress-related markers. Furthermore, ML385, an NRF2 inhibitor, reversed these effects of EUG. The present study suggested that EUG exerted protective effects on pancreatic β cells in T1DM by attenuating apoptosis and oxidative stress through the activation of the NRF2 signaling pathway. Consequently, EUG holds great promise as a potential therapeutic candidate for T1DM.